A return to growth at Biogen, Inc. will not be fast, but new CEO Christopher Viehbacher provided assurances during the company’s fourth quarter earnings call on 1 February that a thorough review of operations is under way with options for cutting costs and improving revenue all on the table. However, Viehbacher also noted its Eisai Co., Ltd.-partnered Alzheimer’s disease therapy Leqembi (lecanemab) is not likely to be a meaningful contributor until certain bottlenecks are cleared.
Biogen CEO Plots A Slow Return To Growth As Revenue Set To Shrink Again In 2023
Cost Cuts, R&D Prioritization, Deals All On The Table
Christopher Viehbacher told his first earnings call as CEO that a review is under way to reverse Biogen’s fortunes, but noted Leqembi will not be a meaningful contributor while treatment and reimbursement bottlenecks remain.
More from New Products
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
More from Scrip
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.